Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291

Celina D'Cruz, Evan Barry, Ryan Henry, Lillian Castriotta, Alwin Schuller, Garry Beran, Susan Ashton, Cath Eberlein, Corinne Reimer, Melanie Frigault, Michael Zinda, Darren Cross, Stephen Fawell

Cancer Res (2015) 75 (15_Supplement): 761.

https://doi.org/10.1158/1538-7445.AM2015-761

Published: 01 August 2015

View article titled, Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291

Journal Articles

Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models

Alwin Schuller, Evan Barry, Rhys Jones, Melanie Frigault, Garry Beran, Ryan Henry, David Linsenmayer, Maureen Hattersley, Aaron Smith, Joanne Wilson, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen Fawell, Edwin Clark, Celina D'Cruz

Cancer Res (2015) 75 (15_Supplement): 1477.

https://doi.org/10.1158/1538-7445.AM2015-1477

Published: 01 August 2015

View article titled, Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models

Journal Articles

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Cancer Res (2015) 75 (12): 2489–2500.

https://doi.org/10.1158/0008-5472.CAN-14-3167

Published: 14 June 2015

View article titled, Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Includes: Supplementary data

Journal Articles

Abstract 2978: Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project

Maria Rivera, Marlen Keil, Karsten Boehnke, Martin Lange, Dirk Schumacher, Reinhold Schäfer, Christian R. Regenbrecht, David Henderson, Ulrich Keilholz, Alexander Kuehn, Amin El-Heliebi, Tabea Hohensee, Johannes Haybäck, Christoph Reinhard, Juan A. Velasco, Hans Lehrach, Pilar Garin-Chesa, Garry Beran, Jens Hoffmann

Cancer Res (2014) 74 (19_Supplement): 2978.

https://doi.org/10.1158/1538-7445.AM2014-2978

Published: 01 October 2014

View article titled, Abstract 2978: Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project

Journal Articles

Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC

Celina D'Cruz, Melanie Frigault, Ammar Adam, Minhui Shen, Garry Beran, Evan Barry, Paul Gavine, Yongxin Ren, Shiming Fan, Feng Zhou, Weiguo Qing, Mike Zinda, Weiguo Su, Edwin Clark

Cancer Res (2014) 74 (19_Supplement): 3114.

https://doi.org/10.1158/1538-7445.AM2014-3114

Published: 01 October 2014

View article titled, Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC

Journal Articles

Abstract 5559: Reciprocal expression of miR-125b and miR-192/miR-200 families define clinically relevant sub-types of colorectal cancer with differential sensitivity to EGFR and MEK targeted agents

Christine M. Chresta, Andreas Schlicker, Garry Beran, Georgia Cerillo, Lodewyk F. A. Wessels, George Orphanides

Cancer Res (2014) 74 (19_Supplement): 5559.

https://doi.org/10.1158/1538-7445.AM2014-5559

Published: 01 October 2014

View article titled, Abstract 5559: Reciprocal expression of miR-125b and miR-192/miR-200 families define clinically relevant sub-types of colorectal cancer with differential sensitivity to EGFR and MEK targeted agents

Journal Articles

Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease.

Gayle Marshall, Susan Ashton, Georgina Speake, Celina D'Cruz, Michael Grondine, Cath Trigwell, Graham Bigley, Garry Beran, Katy Lynaugh, Teresa C. Klinowska

Cancer Res (2013) 73 (8_Supplement): 912.

https://doi.org/10.1158/1538-7445.AM2013-912

Published: 15 April 2013

View article titled, Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease.

Journal Articles

Abstract 2995: Identifying subtypes of colorectal cancer tumors and cell lines with treatment relevance using iterative clustering (iNMF)

Garry Beran, Andreas Schlicker, Christine M. Chresta, Gael McWalter, Alison Pritchard, Susie Weston, Sarah Runswick, Sara Davenport, Kerry Heathcote, Denis Alferez, George Orphanides, Tim French, Lodewyk FA Wessels

Cancer Res (2012) 72 (8_Supplement): 2995.

https://doi.org/10.1158/1538-7445.AM2012-2995

Published: 15 April 2012

View article titled, Abstract 2995: Identifying subtypes of colorectal cancer tumors and cell lines with treatment relevance using iterative clustering (iNMF)

Journal Articles

Abstract LB-455: Reciprocal expression of miR125b and miR192/miR200 families define three clinically relevant sub-types of colorectal cancer with differential sensitivity to EGFR and MEK targeted agents

Christine M. Chresta, Andreas Schlicker, Garry Beran, Georgia Cerillo, Sarah Runswick, Lodewyk Wessels, George Orphanides, Robert Wilkinson

Cancer Res (2012) 72 (8_Supplement): LB-455.

https://doi.org/10.1158/1538-7445.AM2012-LB-455

Published: 15 April 2012

View article titled, Abstract LB-455: Reciprocal expression of miR125b and miR192/miR200 families define three clinically relevant sub-types of colorectal cancer with differential sensitivity to EGFR and MEK targeted agents

Journal Articles

Abstract 4172: Identification of a low PTEN / high PI3Kα expressing subset of squamous non-small-cell lung cancer (NSCLC)

Garry Beran, Xi M. Tang, Marie Cumberbatch, Sally Luke, Pritibha Singh, Alexander Kvist, Sabina Cosulich, Paul D. Smith, Carmen Behrens, Edward S. Kim, Chris Womack, Neil Gray, Ignacio I. Wistuba, David P. Blowers

Cancer Res (2012) 72 (8_Supplement): 4172.

https://doi.org/10.1158/1538-7445.AM2012-4172

Published: 15 April 2012

View article titled, Abstract 4172: Identification of a low PTEN / high PI3Kα expressing subset of squamous non-small-cell lung cancer (NSCLC)

Journal Articles

Abstract 5365: Molecular and pharmacological (EGFRi, MEKi) characterisation of a colorectal cancer (CRC) cell line panel to evaluate cellular phenotype and efficacy of targeted therapies in CRC

Christine M. Chresta, Sarah Runswick, Garry Beran, Sara Davenport, Rowena Callis, Robert W. Wilkinson

Cancer Res (2011) 71 (8_Supplement): 5365.

https://doi.org/10.1158/1538-7445.AM2011-5365

Published: 15 April 2011

View article titled, Abstract 5365: Molecular and pharmacological (EGFRi, MEKi) characterisation of a colorectal cancer (CRC) cell line panel to evaluate cellular phenotype and efficacy of targeted therapies in CRC

Journal Articles

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Cancer Res (2010) 70 (6): 2264–2273.

https://doi.org/10.1158/0008-5472.CAN-09-1577

Published: 14 March 2010

View article titled, Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Includes: Supplementary data

Journal Articles

Biologically driven interpretation reveals molecular signatures predictive of oncogenic addiction to MEK signaling and cell line response to the MEK1/2 inhibitor AZD6244 (ARRY-142886)

Jonathan Dry, Chris Harbron, Mark Hickinson, Alex Graham, Tim French, Kai-Ming Chang, Andrew Cassidy, Garry Beran, Mark Cockeril, Christine Chresta, Nathalie Byrne, Rose McCormack, Paul Smith

Cancer Res (2008) 68 (9_Supplement): 913.

Published: 01 May 2008

View article titled, Biologically driven interpretation reveals molecular signatures predictive of oncogenic addiction to MEK signaling and cell line response to the MEK1/2 inhibitor AZD6244 (ARRY-142886)

Journal Articles

Identification of biomarkers in squamous cell carcinoma tumor cell lines of the head and neck that predict for in vitro sensitivity to gefitinib

D Hickinson, Gayle Marshall, Garry Beran, Andrew Cassidy, Marileila Varella-Garcia, Elizabeth Mills, Marie South, Kerry Acheson, Gael McWalter, Rose McCormack, Graham Alex, Paul Bunn, Tim French, Brian Holloway, Fred Hirsch, Georgina Speake

Cancer Res (2008) 68 (9_Supplement): 2754.

Published: 01 May 2008

View article titled, Identification of biomarkers in squamous cell carcinoma tumor cell lines of the head and neck that predict for <em>in vitro</em> sensitivity to gefitinib

NARROW

Abstract 761: Changing the paradigm for treating drug resistance in NSCLC: Novel combinations of AZD6094, a selective MET inhibitor, and an irreversible, selective (EGFRm/T790M) EGFRTKI, AZD9291

Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Abstract 2978: Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project

Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC

Abstract 5559: Reciprocal expression of miR-125b and miR-192/miR-200 families define clinically relevant sub-types of colorectal cancer with differential sensitivity to EGFR and MEK targeted agents

Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease.

Abstract 2995: Identifying subtypes of colorectal cancer tumors and cell lines with treatment relevance using iterative clustering (iNMF)

Abstract LB-455: Reciprocal expression of miR125b and miR192/miR200 families define three clinically relevant sub-types of colorectal cancer with differential sensitivity to EGFR and MEK targeted agents

Abstract 4172: Identification of a low PTEN / high PI3Kα expressing subset of squamous non-small-cell lung cancer (NSCLC)

Abstract 5365: Molecular and pharmacological (EGFRi, MEKi) characterisation of a colorectal cancer (CRC) cell line panel to evaluate cellular phenotype and efficacy of targeted therapies in CRC

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Biologically driven interpretation reveals molecular signatures predictive of oncogenic addiction to MEK signaling and cell line response to the MEK1/2 inhibitor AZD6244 (ARRY-142886)

Identification of biomarkers in squamous cell carcinoma tumor cell lines of the head and neck that predict for in vitro sensitivity to gefitinib

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only